Viewing Study NCT07262333


Ignite Creation Date: 2025-12-25 @ 3:02 AM
Ignite Modification Date: 2025-12-26 @ 1:42 AM
Study NCT ID: NCT07262333
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-03
First Post: 2025-11-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
Sponsor: Beijing Continent Pharmaceutical Co, Ltd.
Organization:

Study Overview

Official Title: Safety and Pharmacokinetics of Single-dose Hydroxynidone Capsules in Patients With Renal Insufficiency
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability.

Based on the preliminary clinical research, a special population study has been initiated. The aim is to investigate the pharmacokinetic differences and safety of honginone capsules in patients with renal insufficiency and healthy subjects, in order to provide a basis for the clinical medication of patients with renal dysfunction.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: